Follow us on
Search
Close this search box.

Dr. SELCUK GORMEZ

Dr. Selcuk Gormez, Interventional Cardiologist

Dr. SELCUK GORMEZ

Snapshot Highlights

  • Over two decades of dedicated experience in Cardiology.
  • Fellow of the European Society of Cardiology (FESC).
  • Extensive research published in esteemed cardiovascular journals.
  • Specialized in Interventional Cardiology.
  • Affiliated with leading healthcare institutions including Acıbadem Health Group.

Education

  • Dr. Siyami Ersek Chest, Cardiovascular Surgery Training and Research Hospital Cardiology (1997)

  • Istanbul University Istanbul Faculty of Medicine (1992)

Professional Experience

  • Acıbadem Atasehir Hospital (2022 – Present)

  • Acıbadem Health Group Kadıköy Hospital (2010 – 2022)

  • Acıbadem University Faculty of Medicine, Department of Cardiology, Faculty Member (2014 – 2015)

  • Medicana International Hospital (2009 – 2010)

  • Şişli Florence Nightingale Hospital, Department of Interventional Cardiology (2006 – 2009)

  • Corlu Private Healing Hospital (2005 – 2006)

  • Kars State Hospital (1998 – 2005)

  • Gumussuyu Military Hospital (1997 – 1998)

Professional Memberships

  • European Society of Percutaneous Cardiovascular Interventions

  • European Heart Rhythm Association (EHRA)

  • European Heart Failure Association

  • Turkish Cardiology Association

  • Fellow of the European Society of Cardiology (FESC) (2007)

Selected Publications

  • Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non- COVID-19 viral pneumonia. Turkish Society of Cardiology Archive, 49(4), 286-292.

  • Comparison of early and long-term follow-up results of percutaneous mitral balloon valvuloplasty and mitral valve replacement. Brasil Medical Association Revista, 67(1), 58-63.

  • Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-19. Bratislava Medical Journal-Bratislavske Lekarske Listy, 122(8), 582-589.

  • Association between renin-angiotensinaldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study. Journal of Human Hypertension, 35(7), 588-597.

  • Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome. Cardiovascular Pathology, 46, 3-9.

  • Mitral valve repair for ischemic mitral insufficiency: an increased early postoperative risk for the elderly. Turkish Journal of Thoracic and Cardiovascular Surgery, 23(2), 239-244.

  • Mediastinal adipose tissue expresses a pathogenic profile of 11-hydroxysteroid dehydrogenase Type 1 glucocorticoid receptor and CD68 in patients with coronary artery disease. Cardiovascular Pathology, 22(3), 183-188.

  • The role of mediastinal adipose tissue 11-hydroxysteroid dehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease. Cardiovascular Diabetology, 11(1), 115.

  • Two Year Follow-up of Sirolimus Eluting Stents versus Paclitaxel Eluting Stents in Acute Myocardial Infarction. International Journal of Angiology, 21(01), 53-58.

  • Adipose Tissue Gene Expression of Adiponectin, Tumor Necrosis Factor and Leptin in Metabolic Syndrome Patients with Coronary Artery Disease. Internal Medicine, 50(8), 805-810.